ACI Life Sciences
- Biotech or pharma, therapeutic R&D
In 2023, Steve and his team sought a solution that reverses the deleterious effects of osteoarthritis. Setting the bar high, a solution should be inexpensive, reverse the disease, show proof in human samples, and have an understood mechanism of action. Dr. Robert Bowles (Utah) identified a solution that meets these criteria. He demonstrated that a single gene reverses cellular senescence, cells return to normal cellular division, inflammatory markers are reduced, extracellular matrix is restored, and the mechanism is a foundational change in the histone status back to a younger state. Sunac Therapeutics was incorporated in 2024 to take this novel therapeutic to the market. The company is seeking seed funding.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}